Cutia Therapeutics’ BLA for CU-20101 Botulinum Toxin Accepted by China’s NMPA

Bulletin Express

Sep 03

Hong Kong-listed Cutia Therapeutics announced that the National Medical Products Administration (NMPA) has formally accepted the Biologics License Application for CU-20101, a botulinum toxin type A injectable aimed at improving moderate to severe glabellar lines.

CU-20101 is produced without animal-derived materials or human serum albumin, removing the risk of transmissible spongiform encephalopathies and related allergic reactions. Management highlights this manufacturing approach as a potential safety advantage over existing alternatives.

The candidate will broaden Cutia Therapeutics’ dermatological portfolio and is expected to create commercial synergies with the Group’s current skin-care products, supporting efforts to increase market share within China’s aesthetic and therapeutic skin treatment segment.

The company underscores that regulatory acceptance does not guarantee eventual approval or commercialisation. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/news/1173370300"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173370300\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173370300?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-03 06:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173370300","market":"us","top_or_hot":-1,"title":"Cutia Therapeutics’ BLA for CU-20101 Botulinum Toxin Accepted by China’s NMPA","media":"Bulletin Express","content":"<p>Hong Kong-listed Cutia Therapeutics announced that the National Medical Products Administration (NMPA) has formally accepted the Biologics License Application for CU-20101, a botulinum toxin type A injectable aimed at improving moderate to severe glabellar lines.</p>\n<p>CU-20101 is produced without animal-derived materials or human serum albumin, removing the risk of transmissible spongiform encephalopathies and related allergic reactions. Management highlights this manufacturing approach as a potential safety advantage over existing alternatives.</p>\n<p>The candidate will broaden Cutia Therapeutics’ dermatological portfolio and is expected to create commercial synergies with the Group’s current skin-care products, supporting efforts to increase market share within China’s aesthetic and therapeutic skin treatment segment.</p>\n<p>The company underscores that regulatory acceptance does not guarantee eventual approval or commercialisation. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cutia Therapeutics’ BLA for CU-20101 Botulinum Toxin Accepted by China’s NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCutia Therapeutics’ BLA for CU-20101 Botulinum Toxin Accepted by China’s NMPA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-03 06:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong-listed Cutia Therapeutics announced that the National Medical Products Administration (NMPA) has formally accepted the Biologics License Application for CU-20101, a botulinum toxin type A injectable aimed at improving moderate to severe glabellar lines.</p>\n<p>CU-20101 is produced without animal-derived materials or human serum albumin, removing the risk of transmissible spongiform encephalopathies and related allergic reactions. Management highlights this manufacturing approach as a potential safety advantage over existing alternatives.</p>\n<p>The candidate will broaden Cutia Therapeutics’ dermatological portfolio and is expected to create commercial synergies with the Group’s current skin-care products, supporting efforts to increase market share within China’s aesthetic and therapeutic skin treatment segment.</p>\n<p>The company underscores that regulatory acceptance does not guarantee eventual approval or commercialisation. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02487","symbol_name":"科笛-B","start_time":0,"source_url":"","article_id":"1173370300","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173370300","pubTimestamp":1788387721,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hong Kong-listed Cutia Therapeutics announced that the National Medical Products Administration (NMPA) has formally accepted the Biologics License Application for CU-20101, a botulinum toxin type A...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02487":"科笛-B"},"translate_title":"Cutia Therapeutics的CU-20101肉毒杆菌毒素BLA获中国国家药监局受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02487":1},"content_text":"Hong Kong-listed Cutia Therapeutics announced that the National Medical Products Administration (NMPA) has formally accepted the Biologics License Application for CU-20101, a botulinum toxin type A injectable aimed at improving moderate to severe glabellar lines.\nCU-20101 is produced without animal-derived materials or human serum albumin, removing the risk of transmissible spongiform encephalopathies and related allergic reactions. Management highlights this manufacturing approach as a potential safety advantage over existing alternatives.\nThe candidate will broaden Cutia Therapeutics’ dermatological portfolio and is expected to create commercial synergies with the Group’s current skin-care products, supporting efforts to increase market share within China’s aesthetic and therapeutic skin treatment segment.\nThe company underscores that regulatory acceptance does not guarantee eventual approval or commercialisation. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}